A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder

A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder

Purpose Vibegron, a novel, potent β3 agonist, has been approved for clinical use in overactive bladder (OAB) treatment in Japan and the Unites States. We performed a bridging study to investigate the efficacy and safety of a daily 50-mg vibegron (code name JLP-2002) dose in Korean patients with OAB....

Full description

Bibliographic Details
Main Authors: Jung Hyun Shin, Seong Jin Jeong, Sun-Ouck Kim, Cheol Young Oh, Kyung Jin Chung, Dong Gil Shin, Tae Hyo Kim, Joonbeom Kwon, Ju-Hyun Shin, Woong Jin Bae, Kyu-Sung Lee, Myung-Soo Choo
Format: Article
Language:English
Published: Korean Continence Society 2023-06-01
Series:International Neurourology Journal
Subjects:
urinary bladder
overactive
vibegron
β3-adrenoreceptor agonist
Online Access:http://einj.org/upload/pdf/inj-2346022-011.pdf

Internet

http://einj.org/upload/pdf/inj-2346022-011.pdf

Similar Items